Potent inhibition of human immunodeficiency virus type 1 (HIV-1) replication by inducible expression of HIV-1 PR multimers - PubMed (original) (raw)

Comparative Study

Potent inhibition of human immunodeficiency virus type 1 (HIV-1) replication by inducible expression of HIV-1 PR multimers

S J Arrigo et al. J Virol. 1995 Oct.

Abstract

Constructs were generated in which expression of human immunodeficiency virus type 1 (HIV-1) protease (PR) was placed under control of the HIV-1 long terminal repeat, thus requiring the HIV-1 Tat protein for expression of PR. The activity of PR was assessed by cotransfection with a construct producing a Gag substrate. Expression of PR as an intramolecular multimer resulted in a large increase in PR activity in comparison with the level obtained with the expression of PR as a monomer. A cytotoxic effect of PR expression was also exhibited by the constructs expressing PR multimers. CD4+ T-cell lines were generated with a construct producing PR as a linked tetramer and screened for PR activity and inducibility. The replication of HIV-1 in these cell lines was several orders of magnitude reduced in comparison with that in cell lines not expressing PR. Infection in these cell lines could be detected early after infection but disappeared over time. Infection of the PR-expressing cell lines could be increased several orders of magnitude by the addition of a specific inhibitor of PR, U75875 (Upjohn), after infection of the cells, demonstrating that the potent inhibition of HIV-1 replication in these cells was directly due to the expression of PR.

PubMed Disclaimer

Similar articles

• Overexpression of human immunodeficiency virus type 1 protease increases intracellular cleavage of Gag and reduces virus infectivity.
  Luukkonen BG, Fenyö EM, Schwartz S. Luukkonen BG, et al. Virology. 1995 Feb 1;206(2):854-65. doi: 10.1006/viro.1995.1008. Virology. 1995. PMID: 7856098
• Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS.
  Lisziewicz J, Sun D, Smythe J, Lusso P, Lori F, Louie A, Markham P, Rossi J, Reitz M, Gallo RC. Lisziewicz J, et al. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8000-4. doi: 10.1073/pnas.90.17.8000. Proc Natl Acad Sci U S A. 1993. PMID: 8367455 Free PMC article.
• Transdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication.
  Beauparlant P, Kwon H, Clarke M, Lin R, Sonenberg N, Wainberg M, Hiscott J. Beauparlant P, et al. J Virol. 1996 Sep;70(9):5777-85. doi: 10.1128/JVI.70.9.5777-5785.1996. J Virol. 1996. PMID: 8709193 Free PMC article.

Cited by

• A single amino acid substitution in HIV-1 reverse transcriptase significantly reduces virion release.
  Chiang CC, Wang SM, Pan YY, Huang KJ, Wang CT. Chiang CC, et al. J Virol. 2010 Jan;84(2):976-82. doi: 10.1128/JVI.01532-09. Epub 2009 Nov 4. J Virol. 2010. PMID: 19889767 Free PMC article.
• Placement of leucine zipper motifs at the carboxyl terminus of HIV-1 protease significantly reduces virion production.
  Pan YY, Wang SM, Huang KJ, Chiang CC, Wang CT. Pan YY, et al. PLoS One. 2012;7(3):e32845. doi: 10.1371/journal.pone.0032845. Epub 2012 Mar 1. PLoS One. 2012. PMID: 22396796 Free PMC article.
• HIV-1 reverse transcriptase stability correlates with Gag cleavage efficiency: reverse transcriptase interaction implications for modulating protease activation.
  Hsieh SH, Yu FH, Huang KJ, Wang CT. Hsieh SH, et al. J Virol. 2023 Sep 28;97(9):e0094823. doi: 10.1128/jvi.00948-23. Epub 2023 Sep 6. J Virol. 2023. PMID: 37671867 Free PMC article.
• Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease.
  Bukovsky A, Göttlinger H. Bukovsky A, et al. J Virol. 1996 Oct;70(10):6820-5. doi: 10.1128/JVI.70.10.6820-6825.1996. J Virol. 1996. PMID: 8794322 Free PMC article.
• Neutral sphingomyelinase 2 is required for HIV-1 maturation.
  Waheed AA, Zhu Y, Agostino E, Naing L, Hikichi Y, Soheilian F, Yoo SW, Song Y, Zhang P, Slusher BS, Haughey NJ, Freed EO. Waheed AA, et al. Proc Natl Acad Sci U S A. 2023 Jul 11;120(28):e2219475120. doi: 10.1073/pnas.2219475120. Epub 2023 Jul 5. Proc Natl Acad Sci U S A. 2023. PMID: 37406093 Free PMC article.

References

1. 1. Science. 1986 Mar 28;231(4745):1580-4 - PubMed
2. 1. Cell. 1985 Jul;41(3):813-23 - PubMed
3. 1. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4686-90 - PubMed
4. 1. Biochem Biophys Res Commun. 1988 Oct 14;156(1):297-303 - PubMed
5. 1. Nature. 1989 Feb 9;337(6207):576-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Research Materials

  • NCI CPTC Antibody Characterization Program